Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate for Prevention of Bone Loss in Breast Cancer Chemotherapy
NCT00054418Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2003
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Risedronate Arm with Placebo Arm (2 arms). Primary endpoint: Average intra-patient change in lumbar spine (L2-L4, PA) bone mineral density at 1 year. Started Mar 2003; status: completed.
02
Drugs
risedronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00054418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054418.